Qiubin preparation workshop stock busy
Release time:
2021-07-01
6# January 18 , there was a busy scene in the Qiubin preparation workshop of Jianfeng Pharmaceutical. On the eye drops production line, with the operation of the machine, the white bottles filled one by one are transported out and neatly arranged in the stainless steel frame, waiting to be sent to the next process; in the clean area, the employees "are fully armed " , paying close attention to the filling situation; packing, packing, coding ... In each production position, the employees perform their duties and are busy in an orderly manner.
In recent years, with the influence of various factors such as the aging of my country's population, lifestyle changes, increased work intensity, increased allergens, and improper eye use, the incidence of various eye diseases has increased year by year, and the market for ophthalmic drugs The growth is fast, and anti-allergic drugs and macular degeneration drugs are the fast-growing ophthalmic drugs. Spike Pharmaceutical's olopatadine hydrochloride eye drops is a drug for the treatment of allergic conjunctivitis. It is the first of its kind in China to pass the consistency evaluation and won the bid in the fourth batch of national drug centralized procurement in 2 this year. In the procurement cycle, medical institutions will give priority to the use of drugs selected in centralized procurement. 5 June, the new standard began to be implemented. According to the sales plan, Jianfeng Pharmaceutical adjusted the production arrangement scientifically and reasonably to ensure stable market supply.
According to Wang Xiizhong, director of Qiubin Preparation Workshop, the production of olopatadine eye drops takes about hours to complete a batch of production from the production preparation of raw and auxiliary materials to the packaging requirements. Under normal circumstances, it takes about 11 hours to complete a batch of production, plus equipment cleaning and sterilization. The preparation workshop started to produce two batches of olopatadine eye drops a day from 6 May 10 , and completed one cycle of production by 18 . The employees are divided into two shifts, one shift a day, working from 6 in the morning to the end of 3: 4 a.m. the next day. sometimes the clearance is slightly delayed. the first shift has just left work, and the second shift is already preparing for the production of the day.
In order to ensure the smooth progress of the production task, in addition to the personnel in the preparation workshop, the First Manufacturing Department adjusted the production arrangement of Jinxi Powder Injection Workshop, and the adjustment personnel came to support the production and packaging of eye drops first. In order to solve the problems in production in time, the team members of the first manufacturing department took turns on duty and worked overtime until early morning with the employees. Considering the busy production, it is early morning after work, moreover, some employees are far away from home. In order to ensure that employees have enough rest time, the First Manufacturing Department specially applied for two dormitories to work shifts. Because this rush is the first large-scale stock after olopatadine won the bid for centralized procurement, the leaders of the group company and the pharmaceutical company attach great importance to it and go to the production site many times to understand the situation and visit the overtime workers. Pharmaceutical companies have also given a lot of support for production deployment and other aspects.
In order to solve the imbalance of product output and production in each workshop, the First Manufacturing Department has organized mutual learning and training for employees in different workshops and positions in recent years, with the aim of adjusting each other when workshop production is tight or production plans are temporarily adjusted. Zheng Kunwu, manager of the first manufacturing department, said that according to the market situation of olopatadine eye drops, the first manufacturing department will consider updating some equipment to expand production capacity, improve work efficiency and reduce labor costs. At the same time, it will further strengthen the training of one person and multiple posts to ensure sufficient personnel in key positions. (Reporter Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page